Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
about
Iron supplementation for reducing morbidity and mortality in children with HIVIron supplementation for reducing morbidity and mortality in children with HIVPathogenesis of human immunodeficiency virus infectionPyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activityViral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitorsEvaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1Haematological abnormalities associated with paediatric HIV/AIDS in Lagos.Pharmacologic considerations for therapeutic success with antiretroviral agents.Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapyNeurological and psychiatric adverse effects of antiretroviral drugs.Drug induced acute pancreatitis: incidence and severity.Development of inhibitors of reverse transcriptase and protease as therapeutics against HIV infection.Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.Didanosine.Antiretroviral therapy: reverse transcriptase inhibition.Pediatric human immunodeficiency virus infection.Impact of antiretroviral protocols on dynamics of AIDS progression markersDidanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in ratsAntiviral therapy: current concepts and practicesPrevalence of anemia and underlying iron status in naive antiretroviral therapy HIV-infected children with moderate immune suppressionRecommendations in pediatric antiretroviral therapy.Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugsDidanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatmentBioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.Mitochondrial toxicity of antiviral drugs.Management of antiretroviral drug therapy in human immunodeficiency virus infection.Treatment of human immunodeficiency virus infection and its associated complications in children.Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virusSpecific neurologic complications of human immunodeficiency virus type 1 (HIV-1) infection in children.Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses.Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.
P2860
Q24241298-0F445009-BE90-4A1C-81FC-479780E2C041Q24244907-47A5A7B9-87FB-4D0A-8CCD-5955354368EBQ24634681-EE44D6A9-99BA-4BA7-BCFE-411A2A1D2A1FQ28323976-7CCB9D67-F4A2-404B-8E3D-69779EA89A68Q28323994-5EFAEBF7-F0AE-4349-808E-AB11D4FC9A17Q28378655-09E797F4-EB5A-4F40-AC9E-6B194691866BQ33371252-40CA4B37-C2A3-4D72-81C3-95BD44C8BFF8Q33735400-DFA68D79-8411-49E7-952E-A7C8BC42349DQ33979204-F697CEED-7106-4F90-83EC-6D8C003FC04EQ34039419-AA5E7722-C73E-4852-A0EC-BFCD4F4D5DDAQ34409038-A7B755BB-2C29-47A3-9F8D-D4076FD6B5CEQ35174341-C781D982-06B5-48B5-82B2-F92D91BDA479Q35232021-F51039D8-9D3C-418A-B2E4-5A20E3736568Q35255870-29B48B64-CD4C-4EB4-BB40-F13F5F0FAB3FQ35322871-266F6344-BEEC-42CF-89A6-836B093C80A0Q35372072-F96D689B-A853-4A2C-9CD1-F82EBB8587CEQ35567216-70847CF9-E5AE-42C1-9ED4-E5D41C5CD099Q35834444-BEE3A5D4-27CD-4529-8D36-2EA42330CB6BQ35867338-EDB0F545-E799-41FF-9683-8952ACD18993Q36070394-C7299F90-B41E-4AE0-879E-35E136FB5044Q36419471-23524E4E-169E-4A19-9D73-A7E32E48B6F3Q36719674-805338A7-5D00-457D-9D7F-7333DFD40754Q36757759-9FFF3436-B61E-437F-B8D2-79089F727D65Q37392730-73367B59-A2DC-4A5C-AB7D-5CC8B166F85AQ39473876-F6F7138B-A4B1-4B3A-8A16-E725C7A1E43EQ40429889-1C1F8F34-06FF-4560-8B1B-71763159C7B2Q40626125-9A83BB8E-4D5C-43BC-ADDD-79AE4C2F1D1BQ40727613-5174102C-48F3-4C4D-A408-9F7705A816B9Q41819493-ABFE9E03-0FBB-4CED-BBA3-06B806B07C7AQ42501346-487E9F87-257E-46CD-8708-01FB15F122CDQ42614912-81D02D83-5F25-461E-9B0E-97A6252B1B35Q43225836-E37CD1E7-341E-49E2-9287-1F308B999F67Q44582907-B9B90B4F-68E6-43CC-9D25-DB7039371F5F
P2860
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@en
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@nl
type
label
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@en
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@nl
prefLabel
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@en
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@nl
P2093
P1476
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
@en
P2093
Brouwers P
Jarosinski P
P304
P356
10.1056/NEJM199101173240301
P407
P577
1991-01-01T00:00:00Z